vs
西铁城（CIA）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是西铁城的1.8倍（$127.1M vs $72.1M），再鼎医药同比增速更快（17.1% vs 13.5%），西铁城自由现金流更多（$17.5M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 11.7%）
西铁城钟表株式会社，又称西铁城集团，是总部位于日本东京西东京市的知名跨国电子企业，核心业务为腕表制造，是西铁城集团的核心企业。除西铁城品牌腕表外，集团还拥有美国钟表公司宝路华，业务同时涵盖计算器、打印机、医疗设备与精密CNC加工设备制造。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CIA vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.8倍
$72.1M
营收增速更快
ZLAB
高出3.6%
13.5%
自由现金流更多
CIA
多$44.2M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
11.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $72.1M | $127.1M |
| 净利润 | $7.3M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 10.9% | -54.6% |
| 净利率 | 10.2% | — |
| 营收同比 | 13.5% | 17.1% |
| 净利润同比 | 102.7% | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIAZLAB
| Q4 25 | $72.1M | $127.1M | ||
| Q3 25 | $62.8M | $115.4M | ||
| Q2 25 | $65.1M | $109.1M | ||
| Q1 25 | $55.7M | $105.7M | ||
| Q4 24 | $63.5M | $108.5M | ||
| Q3 24 | $61.7M | $101.8M | ||
| Q2 24 | $62.1M | $100.1M | ||
| Q1 24 | $57.7M | $87.1M |
净利润CIAZLAB
| Q4 25 | $7.3M | — | ||
| Q3 25 | $2.4M | $-36.0M | ||
| Q2 25 | $6.5M | $-40.7M | ||
| Q1 25 | $-1.6M | $-48.4M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $2.8M | $-41.7M | ||
| Q2 24 | $4.0M | $-80.3M | ||
| Q1 24 | $4.5M | $-53.5M |
毛利率CIAZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CIAZLAB
| Q4 25 | 10.9% | -54.6% | ||
| Q3 25 | 7.1% | -42.3% | ||
| Q2 25 | 10.6% | -50.3% | ||
| Q1 25 | -3.2% | -53.3% | ||
| Q4 24 | 5.9% | -62.6% | ||
| Q3 24 | 4.9% | -66.6% | ||
| Q2 24 | 5.3% | -76.0% | ||
| Q1 24 | 8.5% | -80.7% |
净利率CIAZLAB
| Q4 25 | 10.2% | — | ||
| Q3 25 | 3.8% | -31.2% | ||
| Q2 25 | 9.9% | -37.3% | ||
| Q1 25 | -2.9% | -45.8% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 4.5% | -40.9% | ||
| Q2 24 | 6.4% | -80.2% | ||
| Q1 24 | 7.9% | -61.4% |
每股收益（稀释后）CIAZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.0M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $235.0M | $715.5M |
| 总资产 | $1.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CIAZLAB
| Q4 25 | $23.0M | $689.6M | ||
| Q3 25 | $23.1M | $717.2M | ||
| Q2 25 | $22.7M | $732.2M | ||
| Q1 25 | $18.4M | $757.3M | ||
| Q4 24 | $29.3M | $779.7M | ||
| Q3 24 | $32.4M | $616.1M | ||
| Q2 24 | $26.3M | $630.0M | ||
| Q1 24 | $23.2M | $650.8M |
股东权益CIAZLAB
| Q4 25 | $235.0M | $715.5M | ||
| Q3 25 | $225.6M | $759.9M | ||
| Q2 25 | $229.0M | $791.7M | ||
| Q1 25 | $218.1M | $810.8M | ||
| Q4 24 | $210.4M | $840.9M | ||
| Q3 24 | $207.6M | $667.7M | ||
| Q2 24 | $191.5M | $704.2M | ||
| Q1 24 | $195.2M | $762.2M |
总资产CIAZLAB
| Q4 25 | $1.8B | $1.2B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.7B | $985.3M | ||
| Q2 24 | $1.7B | $987.4M | ||
| Q1 24 | $1.7B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $17.5M | $-26.7M |
| 自由现金流率自由现金流/营收 | 24.3% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.45× | — |
| 过去12个月自由现金流最近4个季度 | $26.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CIAZLAB
| Q4 25 | $18.0M | $-26.0M | ||
| Q3 25 | $4.7M | $-32.0M | ||
| Q2 25 | $3.5M | $-31.0M | ||
| Q1 25 | $748.0K | $-61.7M | ||
| Q4 24 | $31.9M | $-55.8M | ||
| Q3 24 | $9.7M | $-26.8M | ||
| Q2 24 | $4.6M | $-42.2M | ||
| Q1 24 | $6.8M | $-90.1M |
自由现金流CIAZLAB
| Q4 25 | $17.5M | $-26.7M | ||
| Q3 25 | $4.6M | $-35.0M | ||
| Q2 25 | $3.3M | $-33.9M | ||
| Q1 25 | $641.0K | $-63.2M | ||
| Q4 24 | $31.3M | $-58.4M | ||
| Q3 24 | $9.3M | $-28.2M | ||
| Q2 24 | $4.5M | $-42.9M | ||
| Q1 24 | $6.7M | $-91.1M |
自由现金流率CIAZLAB
| Q4 25 | 24.3% | -21.0% | ||
| Q3 25 | 7.3% | -30.4% | ||
| Q2 25 | 5.1% | -31.1% | ||
| Q1 25 | 1.2% | -59.9% | ||
| Q4 24 | 49.2% | -53.8% | ||
| Q3 24 | 15.1% | -27.7% | ||
| Q2 24 | 7.2% | -42.9% | ||
| Q1 24 | 11.7% | -104.5% |
资本支出强度CIAZLAB
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.2% | 1.5% | ||
| Q4 24 | 1.0% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
现金转化率CIAZLAB
| Q4 25 | 2.45× | — | ||
| Q3 25 | 1.93× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.81× | — | ||
| Q3 24 | 3.48× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIA
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
